Recent advances in the development of animal models for Lyme borreliosis have provided means of identifying potential targets for the design of a subunit vaccine to prevent this disease. The C3H/HeN mouse model was used to study several Borrelia burgdorfieri antigens from a single isolate for their ability to elicit borreliacidal and protective antibodies. The ospA, ospB, ospC, ospD, and 83-kDa genes from a California isolate, SON 188, were cloned and expressed in Escherichia coli as proteins fused to the C-terminal end of maltose-binding protein. 
Lyme borreliosis is a multisystemic disease transmitted by tick bite. The causative agent was identified as the spirochete Borrelia burgdorferi (6) . The salient features of the disease in humans include early flu-like symptoms which, if untreated, may progress to arthritis, carditis, and neurological involvement (44) . Lyme borreliosis is now the most prevalent vectorborne disease in North America (8) . The clinical importance of Lyme borreliosis to veterinary and human medicine has prompted a concerted effort to develop a vaccine for its prevention (12) . Recently, a killed whole-cell vaccine was approved for use in canines (9) . However, the demonstration of cross-reactive epitopes among B. burgdorferi and neural tissue brings to issue the possible risk of autoimmune sequelae when using a whole-cell vaccine (42) . A vaccine comprised of antigenic subunits or components of B. burgdorferi would potentially avoid this problem.
The development of a subunit vaccine for the prevention of Lyme borreliosis has been facilitated by the establishment of several laboratory animal models, including rodent, canine, and primate models (1, 2, 29, 32) . The availability of these models, coupled with the recent cloning and sequencing of several outer surface proteins from B. burgdorferi (3, 17, 30, 35, 47), has been instrumental in identifying antigens with the potential of eliciting protective antibodies. Passive immunization with antibodies recognizing outer surface protein A (OspA) or OspB has proven effective in preventing infection in both the severe combined immunodeficiency and the C3H mouse models (37, 41) . Active immunization using OspA or OspB was also successful in providing protection in immunocompetent C3H mice challenged with B. burgdorferi (13, 14, 45) . More recently, a third antigen, OspC, was found to elicit protective antibodies in gerbils challenged with a European isolate of B. burgdorferi (33) . These 0.5 mM, respectively. Amplification was performed for 30 cycles under the following conditions: 2 min of denaturation at 94°C, 2 min of annealing at 45°C, and 4 min of extension at 72°C. The amplification products were purified with the Magic PCR Preps DNA purification system (Promega).
Cloning and expression of genes. The amplification products were prepared for cloning by treating with the Klenow fragment of DNA polymerase to form blunt ends, cutting with the appropriate restriction enzyme (Table 1) , and phosphorylating with T4 polynucleotide kinase. The cloning vector pMal c2 (New England Biolabs, Beverly, Mass.) was digested with Xmnl and a restriction enzyme corresponding to the unique site engineered into the amplification product (Table 1 ). An exception to this was the cloning of the 83-kDa gene, in which the pMal c2 vector was cut with BamnHI and PstI. Following digestion, the vector was dephosphorylated with calf intestinal alkaline phosphatase, mixed with the amplification product, and ligated overnight at 16°C. E. coli strain DH5(x was transformed with the ligation mixture and cultured on LuriaBertani plates containing ampicillin (100 Lg/ml). Transformants were then screened on Luria-Bertani-ampicillin plates containing isopropylthiogalactoside (IPTG) and X-Gal (5-bromo-4-chloro-3-indolyl-3-D-galactopyranoside). White colonies were selected for further characterization by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting (immunoblotting).
Identity verification of cloned genes by dot blot hybridization. The plasmid constructs were purified from E. coli with the Wizard Miniprep DNA purification system (Promega). Ten nanograms of each plasmid construct was spotted onto a nylon membrane, and the membrane was probed with a digoxigeninlabeled synthetic oligonucleotide probe (Table 2) . Hybridization was performed at 37°C with 5 pmol of each probe per ml. Labeling of the oligonucleotides with digoxigenin and detection of the hybridized probes were performed by using the Genius system (Boehringer Mannheim, Indianapolis, Ind.).
Purification and cleavage of the fusion proteins. Purification and cleavage of the fusion proteins were performed by following the manufacturer's instructions (New England Biolabs). Overnight cultures of transformed E. coli were inoculated into protein content. In each case, the identity of the cloned gene possessed by each transformant was confirmed by specific hybridization of the plasmid construct with the appropriate synthetic oligonucleotide probe (Table 2 ) (data not shown).
The binding of each fusion protein to the amylose resin and subsequent elution resulted in significant enrichment of the fusion proteins. A single major band was observed on the Coomassie blue-stained SDS-PAGE gel for the 3-gal and Osp fusion proteins (Fig. 1A) . The estimated molecular masses of the ,3-gal, OspA, OspB, OspC, and OspD fusion proteins were 56, 69, 74, 66, and 68 kDa, respectively. Conversely, the 83-kDa fusion protein appeared as multiple bands ranging from 40 to 120 kDa. Coomassie blue staining of the 83-kDa fusion protein at quantities equivalent to the OspA and 1-gal fusion proteins failed to produce a detectable band. Therefore, greater amounts of this protein were required for visualization (Fig.  1A, lane 7) . Staining of the SON 188 lysate with Coomassie blue revealed a protein profile similar to that of the reference strain, B31.
Electrophoretic transfer of these samples to nitrocellulose and subsequent probing with mouse anti-SON 188 serum were performed to assess the immunoreactivity of the fusion proteins (Fig. 1B) Immunological analysis of serum from immunized mice. Following the final boost, the antibody response to each immunogen was measured by immunoblotting and borreliacidal assays. Figure 2 illustrates the reactivity of mouse serum from each immunogen group with nitrocellulose strips containing a lysate of SON 188. Antibodies generated against the OspA fusion protein reacted strongly with a 31-kDa band as expected and showed slight cross-reactivity with the 33-kDa OspB band. The OspB immunogen elicited antibodies recognizing a protein of 18 kDa and one of the expected molecular mass of 33 kDa. Faint cross-reactivity of this serum with the 31-kDa OspA band was also detected. Sera from mice immunized with the OspC and OspD fusion proteins generated bands having the expected molecular masses of 22 and 28 kDa, respectively. Antibodies to the 83-kDa fusion protein produced two bands on the nitrocellulose strip, one corresponding to the expected molecular mass of 83 kDa and the other corresponding to a protein of 60 kDa. Serum derived from mice immunized with heat-inactivated SON 188 recognized numerous proteins, the most predominant of which were OspA and OspB. Anti-f-gal serum did not bind any antigens on the nitrocellulose strip.
Antibody titers for each immunogen group were determined by immunoblot and defined as the highest dilution of sera yielding a detectable band. Immunoblot strips were prepared from two sources: factor Xa-cleaved fusion proteins and SON 188 lysate. Cleavage of the fusion proteins with factor Xa and subsequent separation of the products by SDS-PAGE and Western blotting allowed the titration of antibodies reactive with the B. burgdotferi-derived portion of the immunogens. Thus, this assay measured only immunoreactivity specific for the portion of the immunogen derived from B. burgdorferi and not to MBP. Titers exceeding 100,000 were observed for the 83-kDa and all four Osp immunogen groups, with the antiOspA titer exceeding 500,000 (Table 3 ). While immunogen groups demonstrated similar titers against their respective cleaved proteins, titers against the SON 188 lysate were more varied (Table 3) . A 16-fold difference in titer against the SON 188 nitrocellulose strips was observed for those mice immunized with the OspA fusion protein (titer, 2,048,000) compared with that for those mice receiving the OspD fusion protein (titer, 128,000). These differences in titers may reflect the relative difference in expression levels of these proteins by SON 188 (Fig. 2) .
The borreliacidal activity of each serum group was also evaluated (Table 3 ). This assay measured spirochetal growth as a function of pH and was indicated by a change in medium color from red to yellow. These colorimetric changes were monitored at 560 nm. Spirochetal growth was detected as a decrease in A560, whereas spirochetal death was measured as little or no decrease in absorbance. Antiserum against the heat-inactivated SON 188 immunogen demonstrated a high level of borreliacidal activity (titer, 6,400). Antisera to OspA and OspB yielded borreliacidal activities (titer, 1,600) that were 25% of that yielded by the anti-SON 188 sera. No borreliacidal activity was observed with sera from mice in any other immunogen groups.
Protection studies. Following the immunization series, the mice were challenged with 107 SON 188 organisms to ensure an infectivity rate of 100%. Three weeks after challenge, recovery of organisms from ear, bladder, and heart by culture in BSK II was attempted. Table 4 illustrates that organisms were recovered from the tissues of mice receiving the (-gal, OspD, and 83-kDa immunogens. No organisms were recovered from the mice receiving the heat-inactivated SON 188, OspA, OspB, and OspC immunogens. (20) . These observations, along with our findings, suggest that the OspC antigen may be an important addition to the design of an efficacious subunit vaccine. Interestingly, no borreliacidal activity was observed in our assay using anti-OspC mouse serum. This finding indicates that the anti-OspC antibodies generated in this study lack direct cytolytic activity and suggests a complement-independent mechanism of protection such as enhancement of opsonization. An explanation for this lack of borreliacidal activity may be the failure of OspC to elicit an immunoglobulin isotype that efficiently activates complement. Indeed, Schmitz et (10) .
Unlike the osp genes, the gene encoding the 83-kDa protein is chromosomally encoded and highly conserved among B. burgdorferi isolates (23) . The stability of this gene and the potent immunostimulatory nature of the 83-kDa protein prompted its evaluation as a vaccine candidate (31) . This protein was recently described as being identical to the 94-and 100-kDa antigens of B. burgdorferi (11) . Like OspD, the 83-kDa protein elicited a strong antibody response but failed to produce borreliacidal activity and to protect mice. One possible explanation for this observation may be the destruction of important epitopes as a consequence of proteolysis of the 83-kDa fusion protein prior to immunization. Proteolysis of the 83-kDa fu ion protein was observed by SDS-PAGE and Western blot (Fig. 1) . In addition, the 60-kDa band recognized by the anti-83-kDa serum on a Western blot of SON 188 lysate may also represent a degradation product. The heightened susceptibility of native 83-kDa protein and recombinant forms of this protein to degradation has been observed by Luft et al. (25) . Alternatively, the lack of surface exposure demonstrated by Luft et al. provides a more likely explanation of the failure of the 83-kDa fusion protein to elicit protective immunity.
Recent reports describing possible mechanisms by which B. burgdorferi escapes immunological pressures suggest that a single vaccine component may not be sufficient to effectively prevent infection and thus reveal the need for a multicomponent vaccine (16, 28, 36) . Moreover, the extensive genotypic variation observed among the Osps characterized thus far supports the argument for such a vaccine (19, 24, 27, 38) . We have identified three antigenic components important in the design of a subunit vaccine for the prevention of Lyme borreliosis. We are currently investigating the ability of a vaccine consisting of OspA, OspB, and OspC to provide protection against a panel of genetically characterized isolates of B. burgdorferi. Such studies, we hope, will lead to the identification of variant Osps and their inclusion in the formation of a broadly protective vaccine.
